All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Reported results | 2011-002550-32 | A double-blind, placebo-controlled, randomized trial to study the Viaskin® Peanut’s Efficacy and Safety for treating peanut allergy in children and adults. | 2014-07-31 | due-trials |
Completed, but no date, and reported results | 2013-001754-10 | Open-label follow-up study of the VIPES study to evaluate long-term efficacy and safety of the Viaskin Peanut | bad-data | |
Reported results | 2015-002461-37 | A double-blind, placebo-controlled, randomized phase III pivotal trial to assess the efficacy and safety of peanut epicutaneous immunotherapy with viaskin peanut in peanut-allergic children | 2017-08-18 | due-trials |
Not reported Terminated | 2016-002916-42 | Open-label Follow-up Study of the PEPITES Study to Evaluate the Long-term Efficacy and Safety of Viaskin® Peanut (PEOPLE Study) | 2022-10-12 | due-trials |
Listed as ongoing, but also has a completion date and reported results | 2016-003679-23 | A double-blind, placebo-controlled, randomized phase III trial to assess the safety and efficacy of Viaskin® Peanut in peanut-allergic young children 1-3 years of age (EPITOPE study) | 2022-04-27 | bad-data |
Trial is outside EEC, and reported results | 2018-000868-29 | Epicutaneous Immunotherapy (EPIT) for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled Phase I Safety Study in Adult and Pediatric Subjects | bad-data | |
Ongoing | 2018-003323-10 | EPITOPE OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM CLINICAL BENEFIT AND SAFETY OF DBV712 IN PEANUT-ALLERGIC CHILDREN (EPOPEX) | not-yet-due | |
Not reported | 2019-004523-21 | A Phase 2 Study To Evaluate The Sensitivity, Specificity And Safety Of DBV1605, A Ready To Use Atopy Patch Test For The Diagnosis Of Non-Immunoglobulin E Mediated Cow’s Milk Allergy In Children Stu... | 2023-11-02 | due-trials |